Equity to Asset ratio is calculated as total stockholders equity divided by total asset. OncoCyte's Total Stockholders Equity for the quarter that ended in Jun. 2021 was $102.67 Mil. OncoCyte's Total Assets for the quarter that ended in Jun. 2021 was $177.38 Mil.
Therefore, OncoCyte's Equity to Asset Ratio for the quarter that ended in Jun. 2021 was 0.58.
The historical rank and industry rank for OncoCyte's Equity-to-Asset or its related term are showing as below:
NAS:OCX'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.21 Med: 0.6 Max: 0.92
Current: 0.58
-0.21
-
0.92
During the past 8 years, the highest Equity to Asset Ratio of OncoCyte was 0.92. The lowest was -0.21. And the median was 0.60.
NAS:OCX's Equity-to-Asset is ranked lower than
99.99% of the 255
Companies
in the Biotechnology industry.
( Industry Median: 0.64
vs. NAS:OCX: 0.58
)
OncoCyte Equity-to-Asset Historical Data
The historical data trend for OncoCyte's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
OncoCyte Annual Data
Trend
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Equity-to-Asset
0.68
0.43
0.36
0.77
0.60
OncoCyte Quarterly Data
Sep16
Dec16
Mar17
Jun17
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Equity-to-Asset
0.62
0.60
0.60
0.83
0.58
Competitive Comparison
For the Biotechnology subindustry, OncoCyte's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OncoCyte Equity-to-Asset Distribution
For the Biotechnology industry and Healthcare sector, OncoCyte's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where OncoCyte's Equity-to-Asset falls into.
OncoCyte Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
OncoCyte's Equity to Asset Ratio for the fiscal year that ended in Dec. 2020 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OncoCyte (NAS:OCX) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
OncoCyte Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of OncoCyte's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, the company also developing screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through United States and it earns revenue from the sale of diagnostic tests.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
My Gurus
0.02(0.59%) Volume: 137,916 11:59AM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:OCX has been successfully added to your 
